Keros Therapeutics (KROS)
(Real Time Quote from BATS)
$60.30 USD
+0.40 (0.67%)
Updated Oct 4, 2024 12:50 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Keros Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 20 | 0 | 10 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 20 | 0 | 10 |
Selling & Adminstrative & Depr. & Amort Expenses | 170 | 115 | 76 | 47 | 21 |
Income After Depreciation & Amortization | -170 | -115 | -56 | -47 | -11 |
Non-Operating Income | 17 | 10 | 0 | 1 | -2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -153 | -105 | -57 | -46 | -12 |
Income Taxes | 0 | 0 | 2 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -153 | -105 | -59 | -45 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -153 | -105 | -59 | -45 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -169 | -114 | -56 | -46 | -10 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -170 | -115 | -56 | -47 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.45 | 25.24 | 23.33 | 15.51 | NA |
Diluted EPS Before Non-Recurring Items | -5.20 | -4.15 | -2.52 | -2.93 | NA |
Diluted Net EPS (GAAP) | -5.20 | -4.15 | -2.52 | -2.93 | NA |
Fiscal Year end for Keros Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.04 | 0.08 | 0.14 | 0.01 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.04 | 0.08 | 0.14 | 0.01 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 50.48 | 48.57 | 46.60 | 43.29 | 41.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -50.44 | -48.49 | -46.46 | -43.28 | -41.33 |
Non-Operating Income | 5.18 | 5.37 | -8.54 | 3.84 | 3.83 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -45.26 | -43.11 | -40.24 | -39.44 | -37.51 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -45.26 | -43.11 | -40.24 | -39.44 | -37.51 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -45.26 | -43.11 | -40.24 | -39.44 | -37.51 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 36.10 | 35.69 | 30.13 | 29.67 | 29.60 |
Diluted EPS Before Non-Recurring Items | -1.25 | -1.21 | -1.34 | -1.33 | -1.27 |
Diluted Net EPS (GAAP) | -1.25 | -1.21 | -1.34 | -1.33 | -1.27 |